@biofinder.bsky.social
🚨Paper Out!
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
onlinelibrary.wiley.com/doi/10.1111/...
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
October 29, 2025 at 12:32 PM
🚨Paper Out!
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
onlinelibrary.wiley.com/doi/10.1111/...
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
onlinelibrary.wiley.com/doi/10.1111/...
🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden.
🔗Full paper: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
🔗Full paper: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, ...
alz-journals.onlinelibrary.wiley.com
October 27, 2025 at 12:58 PM
🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden.
🔗Full paper: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
🔗Full paper: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
🚨New publication in Brain Communications!
In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper: academic.oup.com/braincomms/a...
In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper: academic.oup.com/braincomms/a...
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s disease
Kumar et al. report distinct cellular effects on measures of β-amyloid and tau. Importantly, they also found cell-level genetic evidence for a role for mic
academic.oup.com
October 7, 2025 at 11:18 AM
🚨New publication in Brain Communications!
In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper: academic.oup.com/braincomms/a...
In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper: academic.oup.com/braincomms/a...
🚨Paper alert🚨
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.
jamanetwork.com
September 16, 2025 at 7:15 AM
🚨Paper alert🚨
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
🚨New publication in Nature Medicine!
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
More details: linkedin.com/feed/update/...
Full paper: www.nature.com/articles/s41...
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
More details: linkedin.com/feed/update/...
Full paper: www.nature.com/articles/s41...
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers - Nature Medicine | The Swedish BioFINDER study
New publication in Nature Medicine!
In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...
linkedin.com
September 15, 2025 at 1:23 PM
🚨New publication in Nature Medicine!
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
More details: linkedin.com/feed/update/...
Full paper: www.nature.com/articles/s41...
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
More details: linkedin.com/feed/update/...
Full paper: www.nature.com/articles/s41...
🚨New paper alert! Our study led by @teanijarv.bsky.social
investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon.
Out now in Nature Communications! 🔗Full article: doi.org/10.1038/s414...
A thread🧵👇
investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon.
Out now in Nature Communications! 🔗Full article: doi.org/10.1038/s414...
A thread🧵👇
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease - Nature Communications
Asymmetrical distribution of tau pathology in Alzheimer’s disease is linked to asymmetrical amyloid-beta deposition, not reduced brain connectivity, suggesting regional vulnerability plays a key role ...
doi.org
September 5, 2025 at 2:39 PM
🚨New paper alert! Our study led by @teanijarv.bsky.social
investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon.
Out now in Nature Communications! 🔗Full article: doi.org/10.1038/s414...
A thread🧵👇
investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon.
Out now in Nature Communications! 🔗Full article: doi.org/10.1038/s414...
A thread🧵👇
🚨New publication in Nature Aging🚨
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
Plasma tau biomarkers for biological staging of Alzheimer’s disease - Nature Aging
Montoliu-Gaya, Salvadó et al. develop a blood-based model using tau biomarkers measured in a single analysis enabling biological staging of Alzheimer’s disease to support the diagnosis, prognosis and ...
nature.com
August 22, 2025 at 2:31 PM
🚨New publication in Nature Aging🚨
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
🚨New paper alert! This study led by Sophie Mastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: nature.com/articles/s41...
A thread🧵👇
A thread🧵👇
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
Nature Communications - CSF α-synuclein seed amplification assays detect Lewy body pathology accurately but are invasive and costly. Here, the authors show that a two-step workflow using...
nature.com
August 6, 2025 at 8:49 AM
🚨New paper alert! This study led by Sophie Mastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: nature.com/articles/s41...
A thread🧵👇
A thread🧵👇
🚨This study led by @anikawuestefeld.bsky.social aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here: doi.org/10.1002/alz....
🧵👇
🧵👇
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) a...
doi.org
August 5, 2025 at 2:16 PM
🚨This study led by @anikawuestefeld.bsky.social aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here: doi.org/10.1002/alz....
🧵👇
🧵👇
New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @thelancetneuro.bsky.social: www.thelancet.com/journals/lan...
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
Baseline and longitudinal plasma p-tau217 were associated with subsequent decline
in global cognition, progression to dementia, and increased tau burden, whereas baseline
p-tau217 and GFAP were associ...
www.thelancet.com
June 27, 2025 at 11:54 AM
New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @thelancetneuro.bsky.social: www.thelancet.com/journals/lan...
🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo.bsky.social from @jwvogel.bsky.social's group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇
How does the brain reorganize in the context of age and AD?
Are functional changes in age and AD similar?
Are these changes dynamic across the age/AD spectrum?
We unpack these questions in a sample of N=973 with AD biomarkers
Preprint: tinyurl.com/ymv8s7h8
⬇️🧵
1/
Are functional changes in age and AD similar?
Are these changes dynamic across the age/AD spectrum?
We unpack these questions in a sample of N=973 with AD biomarkers
Preprint: tinyurl.com/ymv8s7h8
⬇️🧵
1/
May 28, 2025 at 9:49 AM
🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo.bsky.social from @jwvogel.bsky.social's group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/
May 5, 2025 at 12:31 PM
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/
🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented
@xiaoyucaly.bsky.social from @jwvogel.bsky.social group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
@xiaoyucaly.bsky.social from @jwvogel.bsky.social group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
🧠New preprint! What drives tau, the pathological protein in AD, to spread?
We found that WHERE tau appears and HOW MUCH accumulates are governed by different mechanisms. Check it out: www.biorxiv.org/content/10.1...
#MedSky #neuroskyence #neurosky #alzsky #compneuro #MRI #neuroimaging #neurology
We found that WHERE tau appears and HOW MUCH accumulates are governed by different mechanisms. Check it out: www.biorxiv.org/content/10.1...
#MedSky #neuroskyence #neurosky #alzsky #compneuro #MRI #neuroimaging #neurology
www.biorxiv.org
April 25, 2025 at 9:38 AM
🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented
@xiaoyucaly.bsky.social from @jwvogel.bsky.social group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
@xiaoyucaly.bsky.social from @jwvogel.bsky.social group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
‼️New preprint!
We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other.
Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇
We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other.
Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇
April 25, 2025 at 9:35 AM
‼️New preprint!
We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other.
Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇
We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other.
Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇
🚨New paper alert! Research from our group and collaborators at The University of Melbourne shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. 📖Read more here: theconversation.com/brains-of-pe...
Brains of people with schizophrenia may age faster – how our research adds to the evidence
Study suggests accelerated brain ageing is a factor in the development of schizophrenia – and can be measured using a simple blood test.
theconversation.com
April 15, 2025 at 7:47 AM
🚨New paper alert! Research from our group and collaborators at The University of Melbourne shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. 📖Read more here: theconversation.com/brains-of-pe...
New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine
Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.
nature.com
April 9, 2025 at 12:37 PM
New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
Guten Morgen! 👋 Start the day with more presentations from our group.
April 3, 2025 at 7:41 AM
Guten Morgen! 👋 Start the day with more presentations from our group.
Don’t miss out on our #ADPD2025 on-demand presentations about brain reserve in frontotemporal dementia, a sensitive visual read algorithm for assessing tau PET images, and the correlation between biomarkers and and [18F] dopa-pet!
April 1, 2025 at 1:10 PM
Don’t miss out on our #ADPD2025 on-demand presentations about brain reserve in frontotemporal dementia, a sensitive visual read algorithm for assessing tau PET images, and the correlation between biomarkers and and [18F] dopa-pet!
If you’re joining 🧠 #ADPD2025 in Vienna 🇦🇹 this week, don’t miss the BioFINDER posters and presentations!
🩸 Blood based biomarkers, 🧠 tau PET, proteomics, and many other topics!
🩸 Blood based biomarkers, 🧠 tau PET, proteomics, and many other topics!
April 1, 2025 at 8:09 AM
If you’re joining 🧠 #ADPD2025 in Vienna 🇦🇹 this week, don’t miss the BioFINDER posters and presentations!
🩸 Blood based biomarkers, 🧠 tau PET, proteomics, and many other topics!
🩸 Blood based biomarkers, 🧠 tau PET, proteomics, and many other topics!
‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social:
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease - Nature Medicine
Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.
www.nature.com
March 31, 2025 at 2:44 PM
‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social:
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
🚨New publication led by @rikossenkoppele.bsky.social & @gsalvado.bsky.social at @natureaging.bsky.social: www.nature.com/articles/s43...
We compared the role of plasma p-tau217 and tau-PET in predicting cognitive decline in cognitively unimpaired individuals and the implications for clinical trials.
We compared the role of plasma p-tau217 and tau-PET in predicting cognitive decline in cognitively unimpaired individuals and the implications for clinical trials.
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials - Nature Aging
Ossenkoppele, Salvado et al. show that plasma p-tau217 and tau-PET predict cognitive decline equally well among cognitively unimpaired individuals. Their combined use further boosts prognostic accurac...
www.nature.com
March 31, 2025 at 1:18 PM
🚨New publication led by @rikossenkoppele.bsky.social & @gsalvado.bsky.social at @natureaging.bsky.social: www.nature.com/articles/s43...
We compared the role of plasma p-tau217 and tau-PET in predicting cognitive decline in cognitively unimpaired individuals and the implications for clinical trials.
We compared the role of plasma p-tau217 and tau-PET in predicting cognitive decline in cognitively unimpaired individuals and the implications for clinical trials.
🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...
doi.org
February 26, 2025 at 8:31 AM
🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇